IN2014DN09417A - - Google Patents

Info

Publication number
IN2014DN09417A
IN2014DN09417A IN9417DEN2014A IN2014DN09417A IN 2014DN09417 A IN2014DN09417 A IN 2014DN09417A IN 9417DEN2014 A IN9417DEN2014 A IN 9417DEN2014A IN 2014DN09417 A IN2014DN09417 A IN 2014DN09417A
Authority
IN
India
Prior art keywords
present
specific antibodies
antibodies
specificity
affinity
Prior art date
Application number
Inventor
Gerhard Frey
Hwai Wen Chang
Jay M Short
Original Assignee
Bioatla Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Llc filed Critical Bioatla Llc
Publication of IN2014DN09417A publication Critical patent/IN2014DN09417A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention is relevant to the generation of multi- specific antibodies, antibodies that are distinguished by their ability to bind to multiple antigens with specificity and with affinity. In particular, the present invention is related to bi -specific antibodies.
IN9417DEN2014 2012-05-10 2013-05-10 IN2014DN09417A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261645302P 2012-05-10 2012-05-10
PCT/US2013/040575 WO2013170168A1 (en) 2012-05-10 2013-05-10 Multi-specific monoclonal antibodies

Publications (1)

Publication Number Publication Date
IN2014DN09417A true IN2014DN09417A (en) 2015-07-17

Family

ID=49551307

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9417DEN2014 IN2014DN09417A (en) 2012-05-10 2013-05-10

Country Status (13)

Country Link
US (3) US9969813B2 (en)
EP (2) EP2847231B1 (en)
JP (3) JP6267689B2 (en)
KR (3) KR102023401B1 (en)
CN (2) CN108690132B (en)
AU (3) AU2013259276B2 (en)
CA (3) CA2872908C (en)
DK (1) DK2847231T3 (en)
ES (1) ES2749200T3 (en)
HK (1) HK1210620A1 (en)
IN (1) IN2014DN09417A (en)
MX (2) MX2019001355A (en)
WO (1) WO2013170168A1 (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2872908C (en) 2012-05-10 2023-11-14 Gerhard Frey Multi-specific monoclonal antibodies
TWI707038B (en) 2013-08-05 2020-10-11 美商扭轉生物科技有限公司 De novo synthesized gene libraries
ES2913205T3 (en) 2014-05-13 2022-06-01 Bioatla Inc Conditionally active biological proteins
ES3034398T3 (en) 2014-08-28 2025-08-18 Bioatla Inc Conditionally active chimeric antigen receptors for modified t-cells
US11111288B2 (en) 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
WO2016126882A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
HK1258869A1 (en) * 2015-09-18 2019-11-22 Twist Bioscience Corporation Oligonucleic acid variant libraries and synthesis thereof
CN108698012A (en) 2015-09-22 2018-10-23 特韦斯特生物科学公司 Flexible substrates for nucleic acid synthesis
US10697972B2 (en) 2016-01-12 2020-06-30 Bioatla, Llc Diagnostics using conditionally active antibodies
WO2017123537A1 (en) 2016-01-12 2017-07-20 Bioatla, Llc Diagnostics using conditionally active antibodies
JP7082604B2 (en) 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド Multispecific and multifunctional molecules and their use
ES2930255T3 (en) 2016-05-13 2022-12-09 Bioatla Inc Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
US10417457B2 (en) 2016-09-21 2019-09-17 Twist Bioscience Corporation Nucleic acid based data storage
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
US11550939B2 (en) 2017-02-22 2023-01-10 Twist Bioscience Corporation Nucleic acid based data storage using enzymatic bioencryption
US20210246227A1 (en) 2017-05-31 2021-08-12 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
IL271205B2 (en) 2017-06-12 2025-02-01 Twist Bioscience Corp Methods for seamless nucleic acid assembly
EP4088783A1 (en) 2017-08-01 2022-11-16 Ab Studio Inc. Bispecific antibodies and uses thereof
GB2581620A (en) 2017-09-11 2020-08-26 Twist Bioscience Corp GPCR binding proteins and synthesis thereof
CA3079613A1 (en) 2017-10-20 2019-04-25 Twist Bioscience Corporation Heated nanowells for polynucleotide synthesis
AU2018387829B2 (en) 2017-12-22 2024-12-19 Argenx Bvba Bispecific antigen binding construct
GB2585506A (en) 2018-01-04 2021-01-13 Twist Bioscience Corp DNA-based digital information storage
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
GB201802487D0 (en) 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy
US20210009711A1 (en) 2018-03-14 2021-01-14 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CA3100739A1 (en) 2018-05-18 2019-11-21 Twist Bioscience Corporation Polynucleotides, reagents, and methods for nucleic acid hybridization
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2019241216A1 (en) 2018-06-14 2019-12-19 Bioatla, Llc Multi-specific antibody constructs
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
AU2019326407A1 (en) * 2018-08-21 2021-02-18 Bioatla, Inc. Conditionally active proteins with pH selectivity
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
EP3902816A4 (en) 2018-12-26 2022-09-14 Twist Bioscience Corporation Highly accurate de novo polynucleotide synthesis
EP3917579A4 (en) 2019-01-28 2023-03-29 AB Therapeutics, Inc. BISPECIFIC ANTIBODIES AND THEIR USES
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
CN114127112A (en) 2019-02-21 2022-03-01 马伦戈治疗公司 Multifunctional molecules that bind to T cells and their use to treat autoimmune disorders
WO2020172596A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and thereof
AU2020224154B2 (en) 2019-02-21 2025-05-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
JP2022521551A (en) 2019-02-26 2022-04-08 ツイスト バイオサイエンス コーポレーション GLP1 receptor mutant nucleic acid library
AU2020227802A1 (en) 2019-02-26 2021-10-14 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
SG11202109172TA (en) 2019-03-08 2021-09-29 Obsidian Therapeutics Inc Human carbonic anhydrase 2 compositions and methods for tunable regulation
US20240124889A1 (en) 2019-05-07 2024-04-18 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
AU2020298294A1 (en) 2019-06-21 2022-02-17 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
EP4034564A4 (en) 2019-09-23 2023-12-13 Twist Bioscience Corporation VARIANT NUCLEIC ACID LIBRARIES FOR SINGLE DOMAIN ANTIBODIES
US12091777B2 (en) 2019-09-23 2024-09-17 Twist Bioscience Corporation Variant nucleic acid libraries for CRTH2
WO2021084104A1 (en) 2019-10-30 2021-05-06 Bioinvent International Ab Tetravalent antibody molecules
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. CD33-BINDING MULTIFUNCTIONAL MOLECULES AND THEIR USES
JP2023509708A (en) 2020-01-03 2023-03-09 マレンゴ・セラピューティクス，インコーポレーテッド ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF
KR20230028242A (en) 2020-04-24 2023-02-28 마렝고 테라퓨틱스, 인크. Multifunctional molecules that bind to T cell-associated cancer cells and their uses
WO2022046920A2 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
KR20230074487A (en) 2020-08-26 2023-05-30 마렝고 테라퓨틱스, 인크. How to detect TRBC1 or TRBC2
AU2021331076A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
WO2022076474A2 (en) * 2020-10-07 2022-04-14 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof
WO2023023055A1 (en) 2021-08-16 2023-02-23 Renagade Therapeutics Management Inc. Compositions and methods for optimizing tropism of delivery systems for rna
TW202328067A (en) 2021-09-14 2023-07-16 美商雷納嘉德醫療管理公司 Cyclic lipids and methods of use thereof
EP4402121A1 (en) 2021-09-14 2024-07-24 Renagade Therapeutics Management Inc. Acyclic lipids and methods of use thereof
CA3243054A1 (en) 2021-12-23 2025-04-08 Renagade Therapeutics Management Inc. Constrained lipids and methods of use thereof
AU2023251104A1 (en) 2022-04-07 2024-10-17 Renagade Therapeutics Management Inc. Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
ATE240740T1 (en) 1991-03-15 2003-06-15 Amgen Inc PEGYLATION OF POLYPEPTIDES
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int Transgenic non-human animals capable of producing heterologous antibodies
PT670898E (en) 1992-11-24 2004-02-27 Searle & Co POLYEPEPTIDES OF MULTIPLE MOLECULES OF INTERLEUCIN-3 (IL-3)
DK0672142T3 (en) 1992-12-04 2001-06-18 Medical Res Council Multivalent and multi-specific binding proteins as well as their preparation and use
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
ES2126145T3 (en) 1993-09-22 1999-03-16 Medical Res Council ANTIBODY REDIRECTION
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
CA2253904A1 (en) 1996-05-03 1997-11-13 Immunomedics, Inc. Targeted combination immunotherapy of cancer
US7011812B1 (en) 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20030207346A1 (en) * 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
IL138034A0 (en) * 1998-03-27 2001-10-31 Genentech Inc Apo-2 ligand-anti-her-2 antibody synergism
US7833528B2 (en) 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
AU2001272017A1 (en) 2000-06-20 2002-01-02 Immunomedics Inc. Targeted combination immunotherapy of cancer and infectious diseases
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
RU2287534C2 (en) 2000-10-20 2006-11-20 Тугаи Сейяку Кабусики Кайся Degraded antibody as tpo agonist
AU2002250081A1 (en) 2001-02-14 2002-08-28 Uab Research Foundation Combined transductional and transcriptional targeting system for improved gene delivery
BR0207267A (en) 2001-02-19 2004-02-10 Merck Patent Gmbh Artificial proteins with reduced immunogenicity
US20050142539A1 (en) * 2002-01-14 2005-06-30 William Herman Targeted ligands
EP1505148B1 (en) 2002-04-26 2009-04-15 Chugai Seiyaku Kabushiki Kaisha Methods of screening for agonistic antibodies
AU2003250074B2 (en) * 2002-07-18 2010-09-09 Merus N.V. Recombinant production of mixtures of antibodies
AU2013200009B2 (en) * 2002-07-18 2015-05-07 Merus N.V. Recombinant production of mixtures of antibodies
WO2004065611A1 (en) * 2003-01-21 2004-08-05 Chugai Seiyaku Kabushiki Kaisha Method of screening light chain of antibdoy
JP4794301B2 (en) 2003-06-11 2011-10-19 中外製薬株式会社 Antibody production method
US20090191213A9 (en) 2003-07-02 2009-07-30 Novo Nordisk A/S Compositions and methods for regulating NK cell activity
EP1631315B1 (en) * 2003-09-24 2014-07-30 Millennium Pharmaceuticals, Inc. Antibodies which bind human cxcr3
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
JP2008523083A (en) 2004-12-08 2008-07-03 イムノメディクス， インコーポレイテッド Methods and compositions for immunotherapy and detection of inflammatory and immune dysregulated diseases, infectious diseases, pathological angiogenesis and cancer
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
PL1699826T3 (en) 2005-01-05 2009-08-31 F Star Biotechnologische Forschungs Und Entw M B H Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
CA2623517A1 (en) 2005-09-23 2007-04-05 Walter Reed Army Institute Of Research (Wrair) Antibodies with simultaneous subsite specificities to protein and lipid epitopes
CA2646611A1 (en) 2006-03-21 2008-05-22 Genentech, Inc. Combinatorial therapy
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
PL2158315T3 (en) * 2007-06-25 2016-10-31 Methods of modifying antibodies, and modified antibodies with improved functional properties
CN101952312A (en) 2007-07-31 2011-01-19 米迪缪尼有限公司 Multispecific epitope binding proteins and uses thereof
JP2010538012A (en) 2007-08-28 2010-12-09 バイオジェン アイデック マサチューセッツ インコーポレイテッド Compositions that bind to multiple epitopes of IGF-1R
AR066170A1 (en) 2007-09-26 2009-07-29 Genentech Inc ANTI INTEGRINA ALFA 5 BETA 1
EP2113255A1 (en) * 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
CA2727992C (en) * 2008-06-25 2017-10-17 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting tnf.alpha.
US20110152173A1 (en) 2008-07-02 2011-06-23 Emergent Product Development Seattle ,LLC TNF-a ANTAGONIST MULTI-TARGET BINDING PROTEINS
EP2313109A2 (en) 2008-07-02 2011-04-27 Emergent Product Development Seattle, LLC Il6 immunotherapeutics
CA2729810A1 (en) 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc Tgf-.beta. antagonist multi-target binding proteins
CA2729899A1 (en) * 2008-07-14 2010-01-21 Fred J. Stevens Methods for systematic control of protein stability
WO2010014629A1 (en) 2008-07-28 2010-02-04 Trubion Pharmaceuticals, Inc. Multi-specific binding proteins targeting b cell disorders
EA024877B1 (en) 2008-10-02 2016-10-31 Эмерджент Продакт Дивелопмент Сиэтл, Ллс Cd86 antagonist multi-target binding proteins
MA33198B1 (en) 2009-03-20 2012-04-02 Genentech Inc ANTI-HER DI-SPECIFIC ANTIBODIES
CN102369215B (en) 2009-04-02 2015-01-21 罗切格利卡特公司 Multispecific antibodies comprising full length antibodies and single chain fab fragments
PT2483310E (en) 2009-09-29 2014-10-07 Roche Glycart Ag Bispecific death receptor agonistic antibodies
JP2013509200A (en) 2009-10-30 2013-03-14 バイエル・ヘルスケア・エルエルシー Antibody imitation scaffold
CN102770456B (en) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 Multispecific antibodies, antibody analogs, compositions and methods
SI2519543T1 (en) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Heterodimer binding proteins and uses thereof
ES2547142T5 (en) * 2010-02-08 2021-12-09 Regeneron Pharma Mouse common light chain
WO2011109726A2 (en) * 2010-03-05 2011-09-09 Bioatla Llc Homologous multi-specific antibodies
KR101860963B1 (en) * 2010-04-23 2018-05-24 제넨테크, 인크. Production of heteromultimeric proteins
ES2966088T3 (en) 2010-07-16 2024-04-18 Bioatla Inc New methods of protein evolution
JP5997154B2 (en) * 2010-08-16 2016-09-28 ノビミューン エスアー Method for producing multispecific multivalent antibody
RU2620071C2 (en) 2010-11-17 2017-05-22 Чугаи Сеияку Кабушики Каиша Multispecific antigen-binding molecule with alternate function to blood coagulation factor viii function
ES2632583T3 (en) 2011-01-14 2017-09-14 Ucb Biopharma Sprl Antibody that binds to IL-17A and IL-17F
EP2500073A1 (en) 2011-03-17 2012-09-19 ChromaCon AG Method for identification and purification of multi-specific polypeptides
CN107936121B (en) 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 Multispecific FAB fusion proteins and methods of use thereof
WO2013003647A2 (en) 2011-06-28 2013-01-03 Sea Lane Biotechnologies, Llc Multispecific stacked variable domain binding proteins
UA117901C2 (en) 2011-07-06 2018-10-25 Ґенмаб Б.В. METHOD FOR STRENGTHENING THE EFFECTORAL FUNCTION OF THE ORIGINAL POLYEPEPTIDE, ITS OPTIONS AND THEIR APPLICATIONS
EP2543680A1 (en) 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
WO2013049254A1 (en) 2011-09-26 2013-04-04 Jn Biosciences Llc Hybrid constant regions
PL2825553T3 (en) 2012-03-14 2018-12-31 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
US20150086584A1 (en) 2012-03-22 2015-03-26 University Of Miami Multi-specific binding agents
CA2872908C (en) * 2012-05-10 2023-11-14 Gerhard Frey Multi-specific monoclonal antibodies
JP2015520168A (en) 2012-05-24 2015-07-16 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Multispecific antibody
WO2014022592A1 (en) 2012-08-02 2014-02-06 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
KR20140036905A (en) 2012-09-18 2014-03-26 삼성전자주식회사 Protein complex comprising bi-specific antibody
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same

Also Published As

Publication number Publication date
CN108690132A (en) 2018-10-23
US10696750B2 (en) 2020-06-30
KR20190073592A (en) 2019-06-26
DK2847231T3 (en) 2019-10-14
EP3553089A1 (en) 2019-10-16
JP2018082707A (en) 2018-05-31
ES2749200T3 (en) 2020-03-19
CN104583239B (en) 2018-09-18
EP2847231A4 (en) 2016-05-25
AU2013259276A1 (en) 2014-11-27
US20150252119A1 (en) 2015-09-10
JP2015517309A (en) 2015-06-22
CA2872908C (en) 2023-11-14
AU2020202133B2 (en) 2023-02-16
AU2013259276B2 (en) 2018-03-22
US9969813B2 (en) 2018-05-15
EP2847231B1 (en) 2019-07-10
KR101951641B1 (en) 2019-02-25
EP2847231A1 (en) 2015-03-18
JP6723392B2 (en) 2020-07-15
KR102089526B1 (en) 2020-03-17
AU2020202133A1 (en) 2020-04-16
CN104583239A (en) 2015-04-29
US20190153120A1 (en) 2019-05-23
US20180237543A1 (en) 2018-08-23
KR20190019222A (en) 2019-02-26
WO2013170168A1 (en) 2013-11-14
CA3202536A1 (en) 2013-11-14
AU2018201159A1 (en) 2018-03-08
JP6465953B2 (en) 2019-02-06
CA2872908A1 (en) 2013-11-14
AU2018201159B2 (en) 2020-04-30
MX2019001355A (en) 2023-01-17
JP2019088291A (en) 2019-06-13
JP6267689B2 (en) 2018-01-24
HK1210620A1 (en) 2016-04-29
MX362705B (en) 2019-02-01
KR20150008154A (en) 2015-01-21
CN108690132B (en) 2022-10-14
MX2014013590A (en) 2015-05-11
CA3051210A1 (en) 2013-11-14
KR102023401B1 (en) 2019-11-04

Similar Documents

Publication Publication Date Title
IN2014DN09417A (en)
PH12017500915A1 (en) Cd47 antibodies, methods, and uses
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
MX360368B (en) Modified antibody regions and uses thereof.
WO2013064701A3 (en) Specific antibodies and their isolation with anti-idiotypic antibodies
PH12014501758A1 (en) Cd47 antibodies and methods of use thereof
PH12015502565B1 (en) Anti-transferrin receptor antibodies and methods of use
TN2013000292A1 (en) Antibody molecules which bind il-17a and il-17f
EA201491947A1 (en) ANTIBODIES AND IMMUNOCONJUGATES TO LY6E AND METHODS OF APPLICATION
EA201492101A1 (en) ANTIBODIES AGAINST FCRN
NZ739622A (en) Antibodies to tau
MX2014000363A (en) Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses.
SG10201703798YA (en) Antibodies with modified affinity to fcrn that promote antigen clearance
IN2015DN00634A (en)
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
WO2011109726A3 (en) Homologous multi-specific antibodies
MX350335B (en) Antibodies that bind integrin alpha-v beta-8.
WO2013186630A3 (en) Humanized antibodies to ca215
NZ743971A (en) Antibodies to tau